Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.

Kiwi extract, a natural collagenase, offers a medium-effect therapy with fewer side effects compared to Xiaflex. Peptides show potential as collagenase agents, but their safety profile is currently ...

In this video, Tim A. Richardson, MD, shares his thoughts on the need for more genetic testing in prostate cancer as more targeted therapies become available. Richardson is the director of the ...

In this video, Jason M. Hafron, MD, explains how PSMA-PET has enabled the use of more targeted treatment approaches in the management of oligometastatic prostate cancer. Hafron is the chief medical ...

GET improves emotional and psychological outcomes in young Latino testicular cancer survivors, reducing anxiety and depressive symptoms. Significant improvements in goal navigation, goal blockage, and ...

Capivasertib with abiraterone and ADT significantly extended rPFS in PTEN-deficient mHSPC patients compared to placebo in the CAPItello-281 trial. The trial showed a trend toward improved overall ...

"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH. In this video, Andrew C. Peterson, MD, MPH, ...

Emory Urology's residency program is one of the largest in the U.S., offering diverse training across multiple hospital sites. Residents gain extensive clinical experience through rotations in ...

"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.

The revised policy will take effect on January 1, 2025.

The SOLAR-RECUR trial evaluates copper Cu 64 PSMA I&T PET/CT for detecting biochemical recurrence in prostate cancer post-treatment. The trial enrolled 235 patients, focusing on detection and ...